Intravesical therapy for bladder cancer

Bibliography

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA A Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Fleshner NE, HERR HW, Stewart AK, et al. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1996;78:1505-13
   PubMed Web of Science ®Google Scholar
• Shelfo SW, Brady JD. Transurethral resection of bladder cancer: the mainstay of treatment. Atlas Urol Clin North Am 1997;5(2):1-14
   Google Scholar
• Compton CC, Byrd DR, Garcia-Aguilar J, et al. AJCC Cancer Staging Atlas. Springer Science & Business Media; 2012
   Google Scholar
• Maruniak NA, Takezawa K, Murphy WM. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. Springer, New York. J Urol 2002;167:2404-7
   PubMed Web of Science ®Google Scholar
• Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57(1):843-9
   PubMedGoogle Scholar
• Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162(1):74-6
   PubMed Web of Science ®Google Scholar
• Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-3
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. EUA guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-53
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Bassi P, Pavone-Macaluso M, et al. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 2004;45:257-66
   PubMedGoogle Scholar
• Hansel DE, Amin MB, Compérat E, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 2013;63:321-32
   PubMedGoogle Scholar
• Lee MC, Levin HS, Jones JS. The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol 2010;183:921-7
   PubMedGoogle Scholar
• Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010;57:595-606
   PubMed Web of Science ®Google Scholar
• Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907-13
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5; discussion 475–7
   PubMed Web of Science ®Google Scholar
• Brausi M, Witjes JA, Lamm D, et al. A Review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol 2011;186:2158-67
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of Bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179:53-6
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3
   PubMed Web of Science ®Google Scholar
• Brosman SA. Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982;128:27-30
   PubMed Web of Science ®Google Scholar
• Zhao W, Schorey JS, Bong-Mastek M, et al. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 2000;86:83-8
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 2014;11:153-62
   PubMed Web of Science ®Google Scholar
• Pook S-H, Rahmat JNB, Esuvaranathan K, et al. Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic. Oncol Rep 2007;18:1315-20
   PubMed Web of Science ®Google Scholar
• Kelley DR, Haaff EO, Becich M, et al. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical Bacillus Calmette-Guerin. J Urol 1986;135:268-71
   PubMed Web of Science ®Google Scholar
• Sylvester R, Vandermeijden A, Witjes J, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91
   PubMed Web of Science ®Google Scholar
• Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 1992;147:1020-3
   PubMed Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur Urol Suppl 2008;7:667-74
   Web of Science ®Google Scholar
• Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600
   PubMed Web of Science ®Google Scholar
• Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000;37(Suppl 1):33-6
   PubMed Web of Science ®Google Scholar
• Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935-9
   PubMed Web of Science ®Google Scholar
• van der Meijden APM, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research And Treatment Of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-23
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, et al. Intravesical Bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485-90
   PubMed Web of Science ®Google Scholar
• Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol 2009;56:247-56
   PubMed Web of Science ®Google Scholar
• Järvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260-5
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6; discussion 686–7
   PubMed Web of Science ®Google Scholar
• Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7
   PubMed Web of Science ®Google Scholar
• Lamm D, Persad R, Brausi M, et al. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 2014;191:20-7
   PubMed Web of Science ®Google Scholar
• Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995;75:552-9
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000;163:1124-9
   PubMed Web of Science ®Google Scholar
• Palou J, Laguna P, Millán-Rodríguez F, et al. Control group and maintenance treatment with Bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001;165:1488-91
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-72
   PubMed Web of Science ®Google Scholar
• Martínez-Piñeiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-80
   PubMed Web of Science ®Google Scholar
• Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007;52:1398-406
   PubMed Web of Science ®Google Scholar
• Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 2009;9:815-20
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006;175:1634-9; discussion 1639–40
   PubMed Web of Science ®Google Scholar
• Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118-25
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164:685-9
   PubMed Web of Science ®Google Scholar
• Herr H, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-9
   PubMed Web of Science ®Google Scholar
• Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005;66:108-25
   PubMed Web of Science ®Google Scholar
• Coplen DE, Marcus MD, Myers JA, et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical Bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990;144(3):652-7
   PubMedGoogle Scholar
• Belldegrun AS, Franklin JR, O’Donnell MA, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793-801
   PubMed Web of Science ®Google Scholar
• Boccardo F, Cannata D, Rubagotti A, et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994;12:7-13
   PubMed Web of Science ®Google Scholar
• Rajala P, Kaasinen E, Raitanen M, et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study–FinnBladder III long-term results. J Urol 2002;168:981-5
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology 1997;50:529-35
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999;162:2399-405
   PubMed Web of Science ®Google Scholar
• Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 1999;161:977-83
   PubMedGoogle Scholar
• Papageorgiou A, Dinney CPN, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 2007;6:872-9
   Google Scholar
• Slaton JW, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34
   PubMed Web of Science ®Google Scholar
• Downs TM, Szilvasi A, O’Donnell MA. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J Urol 1997;158:2311-15
   PubMedGoogle Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010;184:1915-19
   PubMed Web of Science ®Google Scholar
• Lam JS, Benson MC, O’Donnell MA, et al. Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 2003;21:354-60
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose Bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom Bacillus Calmette-Guerin alone previously failed. J Urol 2001;166:1300-4; discussion 1304–5
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. J Urol 2006;24:344-8
   Google Scholar
• Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761-7
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. Cancer 2010;116:1893-900
   PubMed Web of Science ®Google Scholar
• Pode D, Alon Y, Horowitz AT, et al. The mechanism of human bladder tumor implantation in an in vitro model. J Urol 1986;136:482-6
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Kurth KH, Schröder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-52
   PubMed Web of Science ®Google Scholar
• Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-8
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90
   PubMed Web of Science ®Google Scholar
• Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008;179:101-5; discussion 105–6
   PubMed Web of Science ®Google Scholar
• Gudjónsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009;55:773-80
   PubMed Web of Science ®Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676-80
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-19
   PubMed Web of Science ®Google Scholar
• Cookson MS, Chang SS, Lihou C, et al. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol 2014;6:181-91
   PubMedGoogle Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille calmette-guérin–refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006;24(18):2729-34
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002;20:3193-8
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010;28:543-8
   PubMed Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol 2013;190:1200-4
   PubMed Web of Science ®Google Scholar
• Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976;3:121-39
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, David Crawford E, et al. Randomized intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol 1995;1:119-26
   PubMedGoogle Scholar
• Oddens JR, van der Meijden APM, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 2004;46:336-8
   PubMed Web of Science ®Google Scholar
• Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med 1955;252:879-87
   PubMed Web of Science ®Google Scholar
• Gallagher SM. From the battlefield to the bladder: the development of thioTEPA. WJCU 2014;3:195
   Google Scholar
• Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Canc Netw 2006;4:1027-36
   PubMedGoogle Scholar
• Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology 1985;26:27-9
   PubMed Web of Science ®Google Scholar
• Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 1988;140:1390-3
   PubMed Web of Science ®Google Scholar
• Hollister D, Coleman M. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. JAMA 1980;244:2065-7
   PubMedGoogle Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41
   PubMed Web of Science ®Google Scholar
• Ali-El-Dein B, El-Baz M, Aly A, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997;158(1):68-73. discussion 73-4
   PubMed Web of Science ®Google Scholar
• Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-5
   PubMed Web of Science ®Google Scholar
• Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003;21:697-703
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273-8
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270-6
   PubMed Web of Science ®Google Scholar
• Arends TJH, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol 2014;192:708-13
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170:777-82
   PubMed Web of Science ®Google Scholar
• Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 1998;51:506-9
   PubMed Web of Science ®Google Scholar
• Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12:305-13
   PubMed Web of Science ®Google Scholar
• Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012;188:2391-7
   PubMed Web of Science ®Google Scholar
• Wang H, Cai Z, Yang F, et al. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer. Urology 2014;83:508; e13–9
   PubMedGoogle Scholar
• Simpson GR, Horvath A, Annels NE, et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer 2012;106:496-507
   PubMed Web of Science ®Google Scholar
• Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012;98:893-7
   PubMed Web of Science ®Google Scholar
• Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 2012;4:143ra100
   PubMed Web of Science ®Google Scholar
• Rovner ES, Dmochowski RR, Leach GE, et al. A randomized, controlled clinical trial of a novel intravesical pressure attenuation device for the treatment of stress urinary incontinence. J Urol 2013;190:2243-50
   PubMedGoogle Scholar